Uqba Khan
Overview
Explore the profile of Uqba Khan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
534
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hissong E, Bhinder B, Kim J, Ohara K, Ravichandran H, Al Assaad M, et al.
Res Sq
. 2024 Aug;
PMID: 39108491
Colorectal carcinoma (CRC) is a heterogeneous group of tumors with varying therapeutic response and prognosis, and evidence suggests the tumor immune microenvironment (TIME) plays a pivotal role. Using advanced molecular...
2.
Dharmapuri S, Ozbek U, Jethra H, Jun T, Marron T, Saeed A, et al.
World J Gastrointest Oncol
. 2023 Dec;
15(11):1900-1912.
PMID: 38077640
Background: A well-recognized class effect of immune checkpoint inhibitors (ICI) is immune-related adverse events (IrAEs) ranging from low grade toxicities to life-threatening end organ damage requiring permanent discontinuation of ICI....
3.
Kasi P, Hidalgo M, Jafari M, Yeo H, Lowenfeld L, Khan U, et al.
Oncogene
. 2023 Sep;
42(44):3252-3259.
PMID: 37731056
In patients with locally advanced cancer without distant metastases, the neoadjuvant setting presents a platform to evaluate new drugs. For mismatch repair proficient/microsatellite stable (pMMR/MSS) colon and rectal cancer, immunotherapy...
4.
Karim F, Amin A, Liu M, Vishnuvardhan N, Amin S, Shabbir R, et al.
Cancers (Basel)
. 2023 Aug;
15(16).
PMID: 37627127
Purpose: This article reviews the essential clinical trials that have led to these immunotherapy approvals and explores the use of predictive biomarkers, such as PD-L1 expression and MSI status, to...
5.
Shah M, Kennedy E, Alarcon-Rozas A, Alcindor T, Bartley A, Malowany A, et al.
J Clin Oncol
. 2023 Jan;
41(7):1470-1491.
PMID: 36603169
Purpose: To develop recommendations involving targeted therapies for patients with advanced gastroesophageal cancer. Methods: The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of...
6.
Talbot T, DAlessio A, Pinter M, Balcar L, Scheiner B, Marron T, et al.
Liver Int
. 2022 Dec;
43(3):695-707.
PMID: 36577703
Background And Aims: Different approaches are available after the progression of disease (PD) to immune checkpoint inhibitors (ICIs) for hepatocellular carcinoma (HCC), including the continuation of ICI, treatment switching to...
7.
Singh A, Zahid S, Noginskiy I, Pak T, Usta S, Barsoum M, et al.
Curr Oncol
. 2022 Sep;
29(9):6445-6462.
PMID: 36135076
Hepatocellular carcinoma remains a leading cause of cancer-related deaths worldwide. Liver disease including cirrhosis and viral hepatitis remains among the leading causes of hepatocellular carcinoma and despite increased screening, many...
8.
Fatalistic cancer beliefs and self-reported cancer screening behaviors among diverse urban residents
Pinheiro L, Soroka O, Razon D, Antoine F, Rothman J, Kanis M, et al.
J Behav Med
. 2022 Sep;
45(6):954-961.
PMID: 36083412
Cancer fatalism-the belief that death is inevitable when cancer is present-has been identified as a barrier to cancer screening, detection, and treatment. Our study examined the relationship between self-reported cancer...
9.
Marinelli B, Kim E, DAlessio A, Cedillo M, Sinha I, Debnath N, et al.
J Immunother Cancer
. 2022 Jun;
10(6).
PMID: 35710293
Background: Immune checkpoint inhibitors (ICIs) have revolutionized treatment of advanced hepatocellular carcinoma. Integrated use of transarterial chemoembolization (TACE), a locoregional inducer of immunogenic cell death, with ICI has not been...
10.
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
Sharma R, Pillai A, Marron T, Fessas P, Saeed A, Jun T, et al.
Hepatol Commun
. 2022 Apr;
6(7):1776-1785.
PMID: 35481940
The availability of immune checkpoint inhibitors (ICIs) for the management of advanced hepatocellular cancer (HCC) has changed the treatment paradigm. There are emerging questions regarding the efficacy of subsequent anticancer...